Background: Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of cells that expand in cancer, inflammation, and infection and negatively regulate inflammation and the immune response. Heart failure (HF) is a complex clinical syndrome wherein inflammation induction and incomplete resolution can potentially contribute to HF development and progression. However, the role of MDSCs in HF remains unclear. Methods: The percentage of MDSCs in patients with HF and in mice with pressure overload-induced HF using isoproterenol infusion or transverse aortic constriction (TAC) was detected by flow cytometry. The effects of MDSCs on isoproterenol- or TAC-induced HF were observed on depleting MDSCs with 5-fluorouracil (50 mg/kg) or gemcitabine (120 mg/kg), transferring purified MDSCs, or enhancing endogenous MDSCs with rapamycin (2 mgkg(-1)d(-1)). Hypertrophic markers and inflammatory factors were detected by ELISA, real-time polymerase chain reaction, or Western blot. Cardiac functions were determined by echocardiography and hemodynamic analysis. Results: The percentage of human leukocyte antigen-D-related (HLA-DR)(-)CD33(+)CD11b(+) MDSCs in the blood of patients with HF was significantly increased and positively correlated with disease severity and increased plasma levels of cytokines, including interleukin-6, interleukin-10, and transforming growth factor-. Furthermore, MDSCs derived from patients with HF inhibited T-cell proliferation and interferon- secretion. Similar results were observed in TAC- and isoproterenol-induced HF in mice. Pharmaceutical depletion of MDSCs significantly exacerbated isoproterenol- and TAC-induced pathological cardiac remodeling and inflammation, whereas adoptive transfer of MDSCs prominently rescued isoproterenol- and TAC-induced HF. Consistently, administration of rapamycin significantly increased endogenous MDSCs by suppressing their differentiation and improved isoproterenol- and TAC-induced HF, but MDSC depletion mostly blocked beneficial rapamycin-mediated effects. Mechanistically, MDSC-secreted molecules suppressed isoproterenol-induced hypertrophy and proinflammatory gene expression in cardiomyocytes in a coculture system. Neutralization of interleukin-10 blunted both monocytic MDSC- and granulocytic MDSC-mediated anti-inflammatory and antihypertrophic effects, but treatment with a nitric oxide inhibitor only partially blocked the antihypertrophic effect of monocytic MDSCs. Conclusions: Our findings revealed a cardioprotective role of MDSCs in HF by their antihypertrophic effects on cardiomyocytes and anti-inflammatory effects through interleukin-10 and nitric oxide. Pharmacological targeting of MDSCs by rapamycin constitutes a promising therapeutic strategy for HF.
基金:
National Natural Science Foundation [81370347, 81471899]; Integrated Innovative Team for Major Human Diseases Program of Tongji Medical College, Huazhong University of Science and Technology
第一作者单位:[2]Huazhong Univ Sci & Technol, Div Cardiol, Dept Internal Med, Tongji Hosp, Wuhan, Hubei, Peoples R China[3]Huazhong Univ Sci & Technol, Hubei Key Lab Genet & Mol Mech Cardiol Disorders, Tongji Hosp, Wuhan, Hubei, Peoples R China
通讯作者:
通讯机构:[2]Huazhong Univ Sci & Technol, Div Cardiol, Dept Internal Med, Tongji Hosp, Wuhan, Hubei, Peoples R China[3]Huazhong Univ Sci & Technol, Hubei Key Lab Genet & Mol Mech Cardiol Disorders, Tongji Hosp, Wuhan, Hubei, Peoples R China[*1]Huazhong Univ Sci & Technol, Hubei Key Lab Genet & Mol Mech Cardiol Disorders, Tongji Med Coll, Div Cardiol,Dept Internal Med,Tongji Hosp, Wuhan 430030, Hubei, Peoples R China
推荐引用方式(GB/T 7714):
Zhou Ling,Miao Kun,Yin Bingjiao,et al.Cardioprotective Role of Myeloid-Derived Suppressor Cells in Heart Failure[J].CIRCULATION.2018,138(2):181-197.doi:10.1161/CIRCULATIONAHA.117.030811.
APA:
Zhou, Ling,Miao, Kun,Yin, Bingjiao,Li, Huaping,Fan, Jiahui...&Wang, Dao Wen.(2018).Cardioprotective Role of Myeloid-Derived Suppressor Cells in Heart Failure.CIRCULATION,138,(2)
MLA:
Zhou, Ling,et al."Cardioprotective Role of Myeloid-Derived Suppressor Cells in Heart Failure".CIRCULATION 138..2(2018):181-197